Activin and Inhibin

FASN-IN-3 is a fatty acid synthase ( FASN ) inhibitor extracted from patent US20170119786A1, compound 242AIn VitroHuman PBMC and monocytes in cell cultures are stimulated with lipopolysaccharide (LPS), a Toll 4 receptor agonist, or lipoteichoic acid

FASN-IN-3 is a fatty acid synthase ( FASN ) inhibitor extracted from patent US20170119786A1, compound 242AIn VitroHuman PBMC and monocytes in cell cultures are stimulated with lipopolysaccharide (LPS), a Toll 4 receptor agonist, or lipoteichoic acid

FASN-IN-3 is a fatty acid synthase ( FASN ) inhibitor extracted from patent US20170119786A1, compound 242AIn VitroHuman PBMC and monocytes in cell cultures are stimulated with lipopolysaccharide (LPS), a Toll 4 receptor agonist, or lipoteichoic acid

FASN-IN-3 is a fatty acid synthase ( FASN ) inhibitor extracted from patent US20170119786A1, compound 242AIn VitroHuman PBMC and monocytes in cell cultures are stimulated with lipopolysaccharide (LPS), a Toll 4 receptor agonist, or lipoteichoic acid

FASN-IN-4 is a potent inhibitor of fatty acid synthase ( FASN ) with an IC 50 of 10 nM (WO2012064642A1, compound 29) FASN-IN-4 also inhibits SARS-CoV-2 with an EC 50 of 18.6 nM .In VitroThe FASN inhibitor, FASN-IN-4 inhibits SARS-CoV-2 replication,

FASN-IN-4 tosylate is a potent inhibitor of fatty acid synthase ( FASN ) with an IC 50 of 10 nM (WO2012064642A1, compound 29) FASN-IN-4 tosylate also inhibits SARS-CoV-2 with an EC 50 of 18.6 nM .In VitroThe FASN inhibitor, FASN-IN-4 tosylate

FASN-IN-4 tosylate is a potent inhibitor of fatty acid synthase ( FASN ) with an IC 50 of 10 nM (WO2012064642A1, compound 29) FASN-IN-4 tosylate also inhibits SARS-CoV-2 with an EC 50 of 18.6 nM .In VitroThe FASN inhibitor, FASN-IN-4 tosylate

FASN-IN-4 tosylate is a potent inhibitor of fatty acid synthase ( FASN ) with an IC 50 of 10 nM (WO2012064642A1, compound 29) FASN-IN-4 tosylate also inhibits SARS-CoV-2 with an EC 50 of 18.6 nM .In VitroThe FASN inhibitor, FASN-IN-4 tosylate

FASN-IN-4 tosylate is a potent inhibitor of fatty acid synthase ( FASN ) with an IC 50 of 10 nM (WO2012064642A1, compound 29) FASN-IN-4 tosylate also inhibits SARS-CoV-2 with an EC 50 of 18.6 nM .In VitroThe FASN inhibitor, FASN-IN-4 tosylate

FASN-IN-4 tosylate is a potent inhibitor of fatty acid synthase ( FASN ) with an IC 50 of 10 nM (WO2012064642A1, compound 29) FASN-IN-4 tosylate also inhibits SARS-CoV-2 with an EC 50 of 18.6 nM .In VitroThe FASN inhibitor, FASN-IN-4 tosylate

FASN-IN-5 (example 11), a FASN inhibitor, can be used for the research of TH17- or CSF1 -mediated disease or disorder such as cancer , immunological disorders, and obesity.Form:Solid.

FASN-IN-5 (example 11), a FASN inhibitor, can be used for the research of TH17- or CSF1 -mediated disease or disorder such as cancer , immunological disorders, and obesity.Form:Solid.